Ernexa Therapeutics Missed Consensus Estimates

Ernexa Therapeutics (ERNA) reported a loss of $3.40 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $3.30 per share. The company missed consensus estimates by 3.03%.

Ernexa Therapeutics is developing cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa Therapeutics, formerly known as Eterna Therapeutics, is based in CAMBRIDGE, Mass.